{
  "E138A": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138A,G140A,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138A,G140S,Q148H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "E138A,G140S,Y143H,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138A,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138A,S147G,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "E138K": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138K,G140A,Q148K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,G140A,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "E138K,G140A,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "E138K,G140C,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,G140S,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,G140S,Q148R,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,G140S,S147G,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,Q148R,N155H,G163K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138K,S147G,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,Y143C,N155H,G163R,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "E138K,Y143R,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E138T": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "E157Q,G163R": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E157Q,R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN263K": "R263K is a rare non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by EVG and DTG. It confers low-level reductions in EVG susceptibility (~5-fold) and minimal reductions in RAL and DTG susceptibility."
  },
  "E92G": {
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility (~10-fold). It does not reduce RAL or DTG susceptibility."
  },
  "E92G,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility (~10-fold). It does not reduce RAL or DTG susceptibility."
  },
  "E92G,T97A,N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility (~10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "E92Q": {
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,E138K,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,E138K,Y143C,N155H,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,G140S,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92Q,Q95K,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "E92Q,T97A": {
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "E92Q,T97A,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "E92Q,T97A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "E92Q,T97A,Y143H,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "E92Q,T97A,Y143R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "E92Q,Y143H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "E92V,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN92V": "E92V is a rare non-polymorphic mutation selected in vitro by an investigational INSTI. It causes intermediate-level reductions in RAL susceptibility (~10-fold) and high-level reductions in EVG susceptibility (~40-fold)."
  },
  "F121Y": {
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate-level reductions in RAL susceptibility (~10-fold) and high-level reductions in EVG susceptibility (~30-fold)."
  },
  "F121Y,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate-level reductions in RAL susceptibility (~10-fold) and high-level reductions in EVG susceptibility (~30-fold).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "G140A,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "G140A,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148R,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility."
  },
  "G140S,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "G140S,Q148H,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,E157Q,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "G140S,Q148H,N155H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,V151A": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN151A": "V151A is an extremely rare non-polymorphic mutation selected in vitro by an investigational INSTI. It is associated with minimally reduced susceptibility to RAL and EVG."
  },
  "G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "G140S,Q148K,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148N": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148N": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility \u003e10-fold. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K."
  },
  "G140S,Q148N,G163R": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148N": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility \u003e10-fold. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "G140S,Q148R,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R,N155H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Y143H,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "G140S,Y143H,Q148H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Y143R,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "G163K": {
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G163R": {
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "H51Y": {
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility."
  },
  "H51Y,E92Q,G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "H51Y,E92Q,G140S,Q148K,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "H51Y,G140S,Q148K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility."
  },
  "H51Y,T66A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It reduces EVG susceptibility moderately (~5-fold). It does not appear to reduce RAL or DTG susceptibility."
  },
  "L74I,E138K,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,E138K,S147G,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R,R263K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN263K": "R263K is a rare non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by EVG and DTG. It confers low-level reductions in EVG susceptibility (~5-fold) and minimal reductions in RAL and DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,T97A,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74I,T97A,Y143G": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74I,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74I,T97A,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74I,T97A,Y143S": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74I,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,E138K,G140C,Q148R,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,E92Q,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "L74M,G140A,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140C,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140C,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140S,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Q95K,T97A,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,Q95K,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,Q95K,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "L74M,T97A,E138A,Y143C": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,E138K,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,E138K,Y143R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143C,G163R,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143G": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143G,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143R,G163K": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,T97A,Y143S,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "L74M,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Y143C,N155H,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "N155H,E157Q": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "N155H,E157Q,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,E157Q,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN263K": "R263K is a rare non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by EVG and DTG. It confers low-level reductions in EVG susceptibility (~5-fold) and minimal reductions in RAL and DTG susceptibility."
  },
  "N155H,S230R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "N155T": {
    "IN155ST": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility. N155S/T are rare non-polymorphic mutations selected in vitro by investigational INSTIs. They reduce RAL and EVG susceptibility somewhat less than does N155H."
  },
  "P145S": {
    "IN145S": "P145S is a rare non-polymorphic mutation selected in vitro by EVG and rarely in patients receiving EVG. It causes high-level resistance to EVG but not to RAL or DTG."
  },
  "Q146P": {
    "IN146P": "Q146P is a rare non-polymorphic mutation selected in vitro by EVG. It causes intermediate to high-level reductions in EVG susceptibility (~5 to 10-fold)."
  },
  "Q148H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "Q148R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "Q148R,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "Q148R,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "Q95K": {
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "Q95K,T97A,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "Q95K,Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN263K": "R263K is a rare non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by EVG and DTG. It confers low-level reductions in EVG susceptibility (~5-fold) and minimal reductions in RAL and DTG susceptibility."
  },
  "S147G": {
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility."
  },
  "S147G,Q148R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold."
  },
  "S153F": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN153YF": "S153Y/F are rare non-polymorphic mutations selected in vitro by EVG and DTG. S153Y/F cause low-level reductions in susceptibility to each of the INSTIs."
  },
  "S230R": {
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "T66A": {
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It reduces EVG susceptibility moderately (~5-fold). It does not appear to reduce RAL or DTG susceptibility."
  },
  "T66A,E92Q": {
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It reduces EVG susceptibility moderately (~5-fold). It does not appear to reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate-level reductions in RAL susceptibility (5 to 10-fold) and high-level reductions in EVG susceptibility (~30-fold). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold."
  },
  "T66A,G163R": {
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It reduces EVG susceptibility moderately (~5-fold). It does not appear to reduce RAL or DTG susceptibility."
  },
  "T66I": {
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility moderately (~10-fold) but does not appear to reduce RAL or DTG susceptibility."
  },
  "T66I,T97A,G163R": {
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility moderately (~10-fold) but does not appear to reduce RAL or DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T66I,T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility moderately (~10-fold) but does not appear to reduce RAL or DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T66I,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility moderately (~10-fold) but does not appear to reduce RAL or DTG susceptibility."
  },
  "T66K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN66K": "T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG resistance."
  },
  "T66K,L74M,G140S,Q148R,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN66K": "T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG resistance.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they appear to contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "T97A": {
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E138A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E138A,Y143K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E138K": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E138K,E157Q": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E138K,Q148R,N155H,G163K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E138K,S147G,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, they are associated with high-level reductions in RAL and EVG susceptibility (\u003e100-fold) and intermediate reductions in DTG susceptibility (up to 10-fold) when they occur in combination with Q148 mutations. E138T is a rare nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (~5 to 10-fold). It does not reduce RAL or DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,E157Q,G163R": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,F121Y": {
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate-level reductions in RAL susceptibility (~10-fold) and high-level reductions in EVG susceptibility (~30-fold).",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,G140S,Q148R,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with a \u003e100-fold reduction in RAL and EVG susceptibility and an up to 10-fold reduction in DTG susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL and EVG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG susceptibility. In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility up to 10-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,G163K": {
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,G163R": {
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,N155H,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143C,G163R,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143C,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143C,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143H,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143H,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143R,G163K": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143R,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "T97A,Y143S,S230R": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, particularly Y143C/R, it synergistically reduces susceptibility to EVG and RAL."
  },
  "V151A": {
    "IN151A": "V151A is an extremely rare non-polymorphic mutation selected in vitro by an investigational INSTI. It is associated with minimally reduced susceptibility to RAL and EVG."
  },
  "V151L": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN151L": "V151L is an extremely rare non-polymorphic mutation selected in vitro by early investigational INSTIs but not in patients receiving current INSTIs. It confers intermediate / high-level reduced susceptibility to RAL and EVG (~10-to 20-fold) and low-level reduced susceptibility to DTG (~2-fold)."
  },
  "Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility."
  },
  "Y143C,E157Q,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163K,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163R,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "Y143C,N155H,E157Q,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,N155H,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143H": {
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases."
  },
  "Y143H,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R which differs from Y by two bases.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "Y143K": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold)."
  },
  "Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility."
  },
  "Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "Y143R,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility."
  },
  "Y143S": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold)."
  },
  "Y143S,N155H,G163K,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG. Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively. N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.",
    "IN163RK": "G163R/K occur in 5% to 10% of subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143S,S230R": {
    "IN143KGSA": "Y143K/G/S/A are extremely rare mutations that cause intermediate reductions in RAL susceptibility (~5 to 10-fold).",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL and EVG. It appears to have minimal, if any, effect on INSTI susceptibility."
  }
}